Efficacy and Safety of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed and/or Refractory Multiple Myeloma: Pooled Analysis of 2 Single Arm Studies

被引：1

作者：

Jakubowiak, Andrzej ^{[1
]}

Jasielec, Jagoda ^{[2
]}

Rosenbaum, Cara ^{[3
]}

Orlowski, Robert Z. ^{[4
]}

Cohen, Adam ^{[5
]}

Bensinger, William I. ^{[6
]}

Anderson, Aparna ^{[7
]}

Dossett, Tommy ^{[7
]}

Iskander, Karim ^{[8
]}

Mezzi, Khalid ^{[8
]}

Welliver, Timothy ^{[8
]}

Yusuf, Akeem ^{[8
]}

Durie, Brian ^{[9
]}

机构：

[1] Univ Chicago, Chicago, IL 60637 USA

[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[3] Weill Cornell Med Coll, New York, NY USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[6] Swedish Canc Inst, Seattle, WA USA

[7] Stat Collaborat Inc, Washington, DC USA

[8] Amgen Inc, Thousand Oaks, CA 91320 USA

[9] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

carfilzomib; Pomalidomide; relapsed/refractory multiple myeloma;

D O I：

10.1016/j.clml.2019.09.050

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-049

引用

页码：E34 / E34

页数：1

共 50 条

[31] Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
De Novellis, Danilo
Derudas, Daniele
Vincelli, Donatella
Fontana, Raffaele
Della Pepa, Roberta
Palmieri, Salvatore
Accardi, Fabrizio
Rotondo, Francesco
Morelli, Emanuela
Gigliotta, Emilia
Roccotelli, Daniela
Marano, Luana
Barone, Maria Lucia
Cetani, Giusy
Esposito, Daniela
Lazzaro, Antonio
Delle Cave, Giuseppe
Serio, Bianca
Morini, Denise
Porrazzo, Marika
Urciuoli, Eleonora
Masucci, Chiara
Fanelli, Fulvia
Rizzo, Michela
Arcamone, Manuela
Trastulli, Fabio
Rocco, Stefano
Leone, Aldo
Bianco, Rosario
Salvatore, Flavia
Idato, Aurora
Sicari, Maria
Tosi, Patrizia
Rascato, Maria Gabriella
Di Perna, Maria
Falcone, Antonietta Pia
Morello, Lucia
Carlisi, Melania
Svanera, Gino
Annunziata, Mario
Frigeri, Ferdinando
Califano, Catello
Carella, Angelo Michele
Marcacci, Gianpaolo
Pane, Fabrizio
Risitano, Antonio Maria
Giudice, Valentina
Botta, Ciro
Selleri, Carmine
EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (01) : 105 - 114
[32] Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
Plesner, Torben
Arkenau, Hendrik-Tobias
Lokhorst, Henk M.
Gimsing, Peter
Krejcik, Jakub
Lemech, Charlotte
Minnema, Monique C.
Lassen, Ulrik
Laubach, Jacob P.
Ahmadi, Tahamtan
Yeh, Howard
Guckert, Mary E.
Feng, Huaibao
Brun, Nikolai Constantin
Lisby, Steen
Basse, Linda
Palumbo, Antonio
Richardson, Paul G.
BLOOD, 2014, 124 (21)
[33] SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA
Plesner, T.
Arkenau, H. T.
Lokhorst, H. M.
Gimsing, P.
Krejcik, J.
Lemech, C.
Minnema, M. C.
Lassen, U.
Ahmadi, T.
Yeh, H.
Guckert, M.
Brun, N. C.
Lisby, S.
Basse, L.
Palumbo, A.
Richardson, P. G.
HAEMATOLOGICA, 2014, 99 : 104 - 104
[34] AN INDIRECT COMPARISON OF ELOTUZUMAB, CARFILZOMIB, AND DARATUMUMAB WHEN GIVEN IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
Potluri, R.
Chen, C.
Ranjan, S.
Kumar, A.
Bhandari, H.
Davis, C.
VALUE IN HEALTH, 2019, 22 : S104 - S104
[35] Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma
Mark, Tomer M.
Forsberg, Peter A.
Rossi, Adriana C.
Pearse, Roger N.
Pekle, Karen A.
Perry, Arthur
Boyer, Angelique
Tegnestam, Linda
Jayabalan, David
Coleman, Morton
Niesvizky, Ruben
BLOOD ADVANCES, 2019, 3 (04) : 603 - 611
[36] Pomalidomide, Cyclophosphamide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Retrospective Single Center Experience
Garderet, Laurent
Polge, Emmanuelle
Gueye, Mor Seny
Kellil, Chaima
Ova, Jeanny Guelongo Okouango
Beohou, Eric
Labopin, Myriam
Mohty, Mohamad
BLOOD, 2015, 126 (23)
[37] Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
Derman, Benjamin A.
Zonder, Jeffrey
Reece, Donna
Cole, Craig
Berdeja, Jesus
Stefka, Andrew T.
Major, Ajay
Kin, Andrew
Griffith, Kent
Jasielec, Jagoda
Jakubowiak, Andrzej J.
BLOOD ADVANCES, 2023, 7 (19) : 5703 - 5712
[38] The mutational landscape underlying carfilzomib and pomalidomide resistance in relapsed/refractory multiple myeloma
Xu, Jing
Giesen, Nicola
Paramasivam, Nagarajan
Goldschmidt, Hartmut
Brors, Benedikt
Raab, Marc S.
Weinhold, Niels
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E83 - E84
[39] Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone
Hagiwara, May
Panjabi, Sumeet
Sharma, Arati
Delea, Thomas E.
JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (08) : 818 - 829
[40] Carfilzomib-Pomalidomide-Dexamethasone in Anti-CD38 Antibodies and Lenalidomide Relapse/Refractory Multiple Myeloma: A Real Life Monocentric Cohort
Debureaux, Pierre-Edouard
Talbot, Alexis
Forgeard, Nathalie
Elessa, Dikelele
Theves, Floriane
Royer, Bruno
Desrayaud, Nathalie
Citerne, Antoine
Cuccuini, Wendy
Chat, Laureen
Arnulf, Bertrand
Harel, Stephanie
BLOOD, 2023, 142

← 1 2 3 4 5 →